1 / 13

NAPWA’s Treatment Horizons: Pathways to a Functional Cure IAS 2011, Rome, Italy 19th July 2011

Vacc4x: A Therapeutic HIV-1 Vaccine Based on Modified Peptides Maja A. Sommerfelt Ph.D. CSO. NAPWA’s Treatment Horizons: Pathways to a Functional Cure IAS 2011, Rome, Italy 19th July 2011. Therapeutic Vaccination and Functional Cure for HIV-1 Infection. Therapeutic vaccination

madge
Download Presentation

NAPWA’s Treatment Horizons: Pathways to a Functional Cure IAS 2011, Rome, Italy 19th July 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Vacc4x: A Therapeutic HIV-1 Vaccine Based on Modified Peptides Maja A. Sommerfelt Ph.D. CSO NAPWA’s Treatment Horizons: Pathways to a Functional Cure IAS 2011, Rome, Italy 19th July 2011

  2. Therapeutic Vaccination and Functional Cure for HIV-1 Infection • Therapeutic vaccination • Antiviral responses • T-cell approaches:Kill infected cells • Antibody approaches: Block/inactivate the virus • Generalised immune activation induced by HIV • Immune responses induced by therapeutic vaccination can reach regions of the body not accessed by ART • An effective therapeutic vaccine will provide valuable information that can help towards a successful preventative vaccine Vacc-4x Vacc-C5

  3. Vacc-4x: Based on conserved domains of HIV-1 p24CA • 4 modified peptides to p24CA • Sustained immune responses to p24CA are associated with delayed disease progression* • Strong responses to Gag are associated with virus control (LTNP) in the absence of ART¤ • Conserved ‘Sectors’ within p24CA particularly immunologically vulnerable andimportant for virus control§ • Vacc-4x largely corresponds to ‘Sector 3’ p24CA Image WSJ *Weber et al. 1987 Lancet 1:119-22 ; Cheingsov-Popov et al. 1991 BMJ 302 :23-6 ; ¤ Kiepiela et al. 2007 Nature Med. 13:46-53; Zuniga et al. 2006 J. Virol. 80:3122-5. §Dahirel et al. 2011 www.pnas.org/cgi/doi/10.1073/pnas.1105315108; # Schoofs 2011 Wall Street Journal (WSJ) 21st June Images Dahirel et al. 2011

  4. Bionor Immuno Peptide Design Considers Virus Diversity Human Diversity • Conserved Domains • Cross Clade • Most prevalent HLA in • diverse human populations • Human-like sequences excluded • Peptides are modified using a proprietary design technology to improve • Uptake • Antigen processing & presentation • Simple & cost-effective manufacture

  5. Vacc-4x: Phase IIB Study • 135 patients (US+EU); 2/3 active and 1/3 placebo • 6 immunizations (1,2 mg Vacc-4x + GMCSF over 18wks) • Off ART wk 28-52 (LTFU during year 2) Study design • 18-55 y of age • Chronic HIV infection (>1 y) • Stable on ART >6 months (VL < 50 copies/mL) • Pre-study CD4 cell count > 400 x 106 / L • Nadir CD4 cell count > 200 x 106 / L Inclusion criteria • Primary: Resumption of ART • CD4 < 350 x106 / L or 50% decrease • VL >300.000 copies/mL • Co-primary: Change of CD4 • Secondary: Viral Load / ELISPOT / Proliferation / ICS Endpoints

  6. IIB StudySchedule

  7. Vacc-4x IIB study: 18 sites Last Patient Completed wk52: June 2010 Last Patient Completed wk104: June 2011 No Vacc-4x -related SAE reported

  8. Phase IIB Baseline Characteristics

  9. Primary End Points • There was no difference in the time to return to ART (p=0.89) • There was no difference in mean change in CD4 counts over time (p=0.12)

  10. Secondary End Points: Viral Load

  11. Secondary End Points: Viral Load Change from PreART Subjects who remained off ART until week 52. Vacc-4x group change from preART 0.55 log, p=0.0003, n=44. Placebo group change from preART 0.08 log, p=0.89, n=18

  12. Secondary End Points: ELISPOT Responses This indicates a potential  qualitative rather than a quantitative difference in immunological responses to p24 between Vacc-4x and placebo groups. Further immunological analyses are ongoing.

  13. Acknowledgments All Participating Study Volunteers Phase I & IIA Phase IIB Haukeland Hospital Participating Clinical Trial Sites Ullevål University Hospital University of Lausanne & UC Davis Mericon AS SRA Global Clinical Development Ltd. Bionor Laboratories AS Covance Mericon AS The phase IIB study is supported in part by a grant from the Research Council of Norway GLOBVAC program

More Related